PET Imaging of Subjects Using 124I-PU-AD

Phase 0 Terminated 5 enrolled Samus Therapeutics, Inc. Memorial Sloan Kettering Cancer Center · collab Rockefeller University · collab Weill Medical College of Cornell University · collab

NaSingle-groupOpen-labelDiagnostic

Summary

This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.

Timeline

Start: 2016-04
Primary completion: 2019-06-10
Completion: 2019-06-10

Outcome

Outcome not reported

Stopped: “Company has ceased operations”

Publications

Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PU-AD	Unknown	—	Intravenous